利用现有靶向药物治疗急性髓系白血病的益处
自2017年以来,美国FDA已批准九种药物用于急性髓系白血病适应症,包括Bcl-2抑制剂维奈克拉、两种FLT3抑制剂、两种IDH抑制剂等。部分批准为单药或特定联合用于窄适应症,治疗价值有限。本综述讨论含这些市售靶向治疗的联合方案的持续研究。
要点
- 自2017年FDA批准九种AML靶向药物,部分单药适应症窄、治疗价值有限。
- 口服地西他滨获批用于MDS和CMML,或可替代肠外HMA。
- 综述聚焦含已上市靶向药的联合方案研究。
核心结论
- 部分靶向药物单药或特定联合适应症窄,治疗价值有限,需研究联合方案以发挥其益处。
研究设计与样本
- 综述,讨论含已上市靶向治疗药物的联合方案的持续研究。
主要发现
- 自2017年以来FDA批准九种药物用于AML适应症:维奈克拉、米哚妥林、吉瑞替尼、艾伏尼布、恩西地平、吉妥珠单抗奥唑米星、口服阿扎胞苷、CPX-351和格拉吉布。
- 口服地西他滨(100%可吸收)获批用于骨髓增生异常综合征和慢性粒单核细胞白血病,或可作为肠外低甲基化药物的替代。
临床怎么用
- 可考虑将已上市靶向药物纳入联合方案以提升治疗价值。
- 口服地西他滨或可替代肠外低甲基化药物用于MDS和CMML。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Research has resulted in regulatory approval of nine agents for acute myeloid leukaemia indications by the US Food and Drug Administration since 2017: the Bcl-2 inhibitor, venetoclax; two FLT3 inhibitors, midostaurin and gilteritinib; two IDH inhibitors, ivosidenib (IDH1 inhibitor) and enasidenib (IDH2 inhibitor); the anti-CD33 antibody-drug conjugate, gemtuzumab ozogamicin; the oral, poorly absorbable hypomethylating agent, azacitidine; the liposomal formulation of cytarabine and daunorubicin (5:1 ratio), CPX-351; and the hedgehog signalling pathway inhibitor, glasdegib. A 100% absorbable oral formulation of the hypomethylating agent decitabine was approved for the treatment of myelodysplastic syndrome and chronic myelomonocytic leukaemia, and might be used as an alternative to parenteral hypomethylating agents. Several of the approvals are as single-agent therapies or in specific combinations for narrow indications, thus offering poor treatment value. In this Review, we discuss ongoing research into combinations containing these commercially available targeted therapies for acute myeloid leukaemia.
引用
- Kantarjian H, Short NJ, DiNardo C, et al. Harnessing the benefits of available targeted therapies in acute myeloid leukaemia. Lancet Haematol. 2021. PMID: 34687602. doi:10.1016/S2352-3026(21)00270-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。